With a strong international presence in 149 countries and a turnover of 4.615 billion euros in 2019, Servier employs 22,000 people worldwide.

Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs.

Being completely independent, the Group reinvests an average of 25% of turnover (excluding generics) in research and development and uses all its profits for growth.

Servier was created in 1954, and in 1964 Servier UK was the first subsidiary to open, with just two employees.